Back to search results

C11 ER176 PET Imaging for Post-COVID Syndrome

This study is looking into whether a special type of imaging called Positron Emission Tomography (PET) using a drug called C11 ER176 Tracer can help us understand neuroinflammation (inflammation in the brain) in people with Post-COVID Syndrome. You may be able to join if you are an adult patient at Mayo Clinic who has had a confirmed SARS-CoV-2 (COVID-19) infection and have been seen in their Post COVID Clinic or approved by the MAGPIES research group. The main goal is to measure the level of neuroinflammation using this imaging. The study is currently unclear on its recruitment status and plans to enroll 10 participants.

Study design
This is an observational study with no specified phase, planning to enroll 10 participants. It is not specified if it is randomized or blinded.
What's involved
You would receive the C11 ER176 Tracer through an IV, followed by PET imaging of your brain. You must be able to fully participate in all aspects of the study.
Compensation
Not stated in the trial record.
Follow-up
Neuroinflammation will be measured at a baseline reading only.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07527130

C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome

Not Yet Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~10 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:C11 ER176 Tracer

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Degree of Neuroinflammation
Measured over Baseline reading only

Conditions

COVID-19

Explore related trials

COVID-19 Infection

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Ryan T. Hurt, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Katie Cruz
[email protected]
507-284-5404
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Mayo Clinic patients with a previously confirmed infection with the novel SARS-CoV-2 virus who have been seen in the Post COVID Clinic through GIM Integrative Medicine \& Health Section or approval by MAGPIES research group.
Be able to participate fully in all aspects of the study.
Have understood and signed study informed consent.

Exclusion

Lacking the capacity to consent.
Prisoners and institutionalized individuals.
Reports being currently pregnant, lactating, or are of child-bearing potential or are likely to become pregnant during the LLLT treatment phase and are unwilling to use a reliable form of contraception.
Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants
Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm)
Intrauterine device (IUD)
Total hysterectomy or tubal ligation
Abstinence (no sex).
Those patients that have implants that would prevent them from having a PET Scan.
Patients that have claustrophobia.
Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.

What this trial measures

  • Degree of NeuroinflammationBaseline reading only

    Estimation of areas degree of neuroinflammation determined by the radiologist